Remus Pharmaceuticals Ltd
Pharmaceuticals & Biotechnology | Small Cap
Remus Pharmaceuticals shows a mixed financial picture. The company demonstrates significant strengths in solvency, growth, and coverage ratios, suggesting a solid capital structure and promising expansion. However, it struggles with liquidity, efficiency, financial metrics, and profitability, indicating potential challenges in short-term financial management and revenue generation. While the company's solvency is strong, its ability to convert assets into profits and manage short-term obligations appears weak. The healthcare industry's dynamic nature means Remus Pharmaceuticals needs to address these weaknesses to maintain a competitive edge and ensure long-term sustainability. The company shows promise with interest coverage, suggesting it can comfortably handle its debt obligations. The company shows promise with growth in operating profit, EPS, and assets, which could translate to enhanced shareholder value if properly managed. However, the low scores in liquidity, efficiency and profitability need to be addressed for balanced financial health.
Latest Report
View AllThe Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.
Latest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsNeutral
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio6.00
- Financial Ratio4.20
- Profitability Ratio4.60
- Efficiency Ratio4.67
- Coverage Ratio6.80
- Solvency Ratio10.00
- Liquidity Ratio2.00
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourNeutral
- 2 HoursBullish
- 4 HoursBullish
- 1 DayBullish
- 1 WeekNeutral
- 1 MonthNeutral
Remus Pharmaceuticals shows a mixed financial picture. The company demonstrates significant strengths in solvency, growth, and coverage ratios, suggesting a solid capital structure and promising expansion. However, it struggles with liquidity, efficiency, financial metrics, and profitability, indicating potential challenges in short-term financial management and revenue generation. While the company's solvency is strong, its ability to convert assets into profits and manage short-term obligations appears weak. The healthcare industry's dynamic nature means Remus Pharmaceuticals needs to address these weaknesses to maintain a competitive edge and ensure long-term sustainability. The company shows promise with interest coverage, suggesting it can comfortably handle its debt obligations. The company shows promise with growth in operating profit, EPS, and assets, which could translate to enhanced shareholder value if properly managed. However, the low scores in liquidity, efficiency and profitability need to be addressed for balanced financial health.
Overall Valuation Score
P/E RATIO (TTM)
38.15
Industry Median
28.62
Small Cap Median
27.17
P/E RATIO
25.48
P/B RATIO
2.68
Industry Median
3.17
Small Cap Median
2.62
P/S RATIO
1.08
Industry Median
3.42
Small Cap Median
2.55
Others
PEG RATIO
0.00
EV/EBITDA RATIO
14.55
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹799.95 as on Jun 20, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
The company demonstrates strong growth in operating profit, EPS, and assets, signaling promising expansion and potential for enhanced shareholder value. However, low revenue and net income growth rates indicate areas needing attention to ensure balanced and sustainable growth. These strengths suggest a positive trajectory for the company's future. The company's growth in operating profit, EPS, and assets can lead to increased shareholder value.
| Growth Ratios | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Revenue Growth Rate | 191.08 | 37.74 | |
| Operating Profit Growth Rate | 58.62 | 23.91 | |
| Earnings Per Share (EPS) Growth | 39.29 | 27.39 | |
| Asset Growth Rate | 30.03 | 33.72 | |
| Net Income Growth Rate | 58.33 | 21.05 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The company's financial ratios present a mixed picture. While capital expenditures management is strong, low adjusted EPS, cash EPS, book value per share, and dividend per share indicate areas needing improvement. These factors suggest a need to enhance overall financial performance. The weighted average calculation highlights the impact of the stronger capital expenditure metric.
| Financial Ratios | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 277.6 | 78.65 | 45.98 |
| Cash Earnings Per Share (Cash EPS) | 250 | 66.67 | 40.83 |
| Book Value Per Share | 1570 | 426.67 | 292.5 |
| Dividend Per Share (DPS) | 0.71 | 0.74 | 0.63 |
| Capital Expenditures (CapEx) | 12 | 3.7 | 13.7 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company's profitability ratios are mixed. Strong ROCE and ROA are offset by low gross profit, operating, and net margins, indicating potential weaknesses in revenue generation and cost control. This suggests a need to improve overall profitability. The weighted average calculation highlights the impact of the stronger ROCE and ROA values.
| Profitability Ratios | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Gross Profit Margin | 13.15 | 7.1 | 6.32 |
| Return on Capital Employed (ROCE) | 18.44 | 20 | 17 |
| Return on Equity (ROE) | 15.29 | 14.84 | 13.11 |
| Return on Assets (ROA) | 8.71 | 10.62 | 9.84 |
| Operating Margin | 13.62 | 7.42 | 6.67 |
| Net Margin | 11.27 | 6.13 | 5.39 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The company's efficiency ratios present a mixed picture. While days sales in inventory and receivable days suggest effective management, low turnover ratios across fixed assets, inventory, receivables, and capital indicate potential issues in asset utilization. These inefficiencies could hinder the company's ability to maximize profits and returns. The weighted average calculation highlights the impact of current inefficiencies.
| Efficiency Ratios | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Fixed Asset Turnover Ratio | 15.21 | 38.75 | 47.44 |
| Inventory Turnover Ratio | 4.3 | 12.15 | 12.9 |
| Receivables Turnover Ratio | 1.84 | 5.56 | 6.89 |
| Days Sales in Inventory Ratio | 84.88 | 30.04 | 28.29 |
| Receivable Days | 198 | 65.65 | 52.98 |
| Capital Turnover Ratio | 1.31 | 2.37 | 2.37 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The company demonstrates a strong ability to cover its interest expenses but shows weakness in equity dividend coverage. While the interest coverage ratio suggests financial stability, the lack of equity dividend coverage may concern shareholders. This indicates a need to balance debt obligations with shareholder returns. The weighted average calculation highlights the disproportionate impact of interest coverage on the overall score.
| Coverage Ratios | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Interest Coverage Ratio | N/A | 48 | 60 |
| Equity Dividend Coverage Ratio | 25 | 33.33 | 50 |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company exhibits a strong solvency position, suggesting a stable capital structure and a low risk of financial distress. This indicates a healthy balance between debt and equity, enabling the company to manage its long-term obligations effectively. This stability provides a solid foundation for future growth and investment. However, it is important to maintain this balance and avoid excessive reliance on debt.
| Solvency Ratios | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Debt Ratio | 0.03 | 0.02 | 0.03 |
| Debt to Equity Ratio | 0.03 | 0.02 | 0.03 |
| Equity Ratio | 0.97 | 0.98 | 0.97 |
| Debt To Asset Ratio | 0.02 | 0.01 | 0.02 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The company's liquidity position is weak, suggesting potential difficulties in meeting its short-term obligations. This could hinder its ability to invest in growth opportunities and respond to unexpected financial challenges. While the company may have sufficient assets, their ability to convert those assets quickly into cash is questionable. The weighted average calculation, heavily influenced by recent performance, amplifies the impact of current liquidity struggles.
| Liquidity Ratios | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Current Ratio | 1.27 | 1.35 | 1.27 |
| Quick Ratio | 1.01 | 1.04 | 0.94 |
| Cash Ratio | 0.08 | 0.05 | 0.06 |
| Operating Cash Flow Ratio | 0.01 | 0.04 | 0.08 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Accent Microcell Ltd | 7.96 | 24.25 | Neutral | 57.00 | 18.28 | 44.00 |
| 2 | Lincoln Pharmaceuticals Ltd | 7.31 | 14.01 | Neutral | 98.00 | 43.88 | 88.00 |
| 3 | NGL Fine Chem Ltd | 6.98 | 39.22 | Overvalued | 73.00 | 67.39 | 48.00 |
| 4 | Medico Remedies Ltd | 6.61 | 37.70 | Overvalued | 17.00 | 1.58 | 13.00 |
| 5 | Kilitch Drugs (India) Ltd | 6.61 | 21.54 | Neutral | 37.00 | 9.27 | 30.00 |
| 6 | Kopran Ltd | 6.60 | 25.82 | Neutral | 62.00 | 6.30 | 26.00 |
| 7 | SMS Lifesciences India Ltd | 6.59 | 21.20 | Undervalued | 45.00 | 70.68 | 19.00 |
| 8 | Infinium Pharmachem Ltd | 6.42 | 26.90 | Neutral | 22.00 | 6.43 | 14.00 |
| 9 | Sakar Healthcare Ltd | 5.81 | 58.66 | Highly Overvalued | 69.00 | 13.70 | 30.00 |
| 10 | Medicamen Biotech Ltd | 5.73 | 32.19 | Neutral | 20.00 | 6.94 | 10.00 |
| 11 | Albert David Ltd | 5.63 | -272.47 | Neutral | 5.00 | -2.62 | -1.00 |
| 12 | Zim Laboratories Ltd | 5.41 | 41.96 | Neutral | 30.00 | 1.11 | 6.00 |
| 13 | Remus Pharmaceuticals Ltd | 5.31 | 25.48 | Neutral | 57.00 | 20.97 | 46.00 |
| 14 | Ind-Swift Laboratories Ltd | 4.95 | 39.28 | Neutral | 45.00 | 4.89 | 41.00 |
| 15 | Venus Remedies Ltd | 4.83 | 23.37 | Neutral | 147.00 | 74.30 | 103.00 |
| 16 | Wanbury Ltd | 4.65 | 28.62 | Neutral | 88.00 | 18.93 | 43.00 |
| 17 | Nectar Lifescience Ltd | 3.83 | -2.67 | Neutral | -59.00 | -2.95 | -293.00 |
The management of Remus Pharmaceuticals shows mixed performance. Strong sales growth is evident, with a TTM growth of 192%. However, the operating profit margin (OPM) has declined from 13% to 7%, suggesting operational inefficiencies. The company's ROCE is 41.31, and ROE is 33.24, indicating efficient use of capital and shareholder funds. Promoter holding is consistently high at around 70%, indicating confidence.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Sales Growth (TTM) | 192% | Aggressive revenue scaling |
| ROCE | 41.31 | Efficient use of capital | |
| ROE | 33.24 | Efficient use of shareholder funds | |
| Promoter Holding | ~70% | High confidence | |
| CONS | Operating Profit Margin | 7% | Declining profitability |
Financial Performance & Growth
Remus Pharmaceuticals demonstrates significant revenue expansion but faces challenges in maintaining profitability margins. The compounded sales growth TTM is 192%, reflecting aggressive revenue scaling. However, OPM has declined from 13% in Mar 2024 to 7% in Mar 2025. This decline in OPM indicates rising expenses relative to sales, which needs monitoring to ensure sustainable profitability.
| Metric | Mar 2024 | Mar 2025 |
|---|---|---|
| Sales Growth (%) | 212 | 620 |
| OPM (%) | 13% | 7% |
Capital Efficiency & Returns
Remus Pharmaceuticals demonstrates strong capital efficiency and returns. The current ROCE is 41.31%, and ROE is 33.24%, indicating efficient use of capital and shareholder funds.
| Metric | Value |
|---|---|
| ROCE % | 41.31 |
| ROE % | 33.24 |
Financial Health & Prudence
Remus Pharmaceuticals maintains a manageable debt level. The borrowings have increased from ₹12 Cr in Mar 2024 to ₹23 Cr in Mar 2025, which is a notable increase. The company's dividend payout is 0% indicating that the company is reinvesting its earnings back into the business rather than distributing them to shareholders.
| Metric | Mar 2024 | Mar 2025 | |---|---| |Borrowings (Cr)| 12 | 23 | |Dividend Payout %|0|0|
Shareholding & Ownership Structure
Remus Pharmaceuticals exhibits a strong and stable ownership structure. Promoter holding has remained consistently high, increasing slightly from 70.60% in Mar 2024 to 70.85% in Mar 2025. Additionally, FII holdings have increased from 3.25% to 4.77%, suggesting growing institutional interest.
| Metric | Mar 2024 | Mar 2025 | |---|---| |Promoter Holding %| 70.60| 70.85| |FII Holding %|3.25|4.77|
The risk assessment for Remus Pharmaceuticals reveals a moderate level of concern. While the company shows strong sales growth and high promoter holding, there are risks associated with declining operating profit margins and increasing borrowings. The decrease in OPM from 13% to 7% indicates potential operational inefficiencies. The increase in borrowings from ₹12 Cr to ₹23 Cr warrants monitoring.
Segment performance volatility
The sales figures show a large degree of variability, with quarterly sales figures showing variability. Sales increased from ₹29 in Sep 2023 to ₹348 in Mar 2025.
| Metric | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 |
|---|---|---|---|---|
| Sales | 29 | 185 | 273 | 348 |
Foreign exchange or interest rate exposure
The company's increasing borrowings from ₹12 Cr to ₹23 Cr may expose it to interest rate risks.
| Metric | Mar 2024 | Mar 2025 | |---|---| |Borrowings|12|23|
Regulatory compliance cost trends
Remus Pharmaceuticals operates in the healthcare sector, which is subject to stringent regulatory requirements.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10807.98Bearish
- SMA 20784.60Bullish
- SMA 50746.47Bullish
- EMA 10798.50Bullish
- EMA 20788.01Bullish
- EMA 50761.24Bullish
- DEMA 10805.67Bearish
- DEMA 20809.69Bearish
- DEMA 50789.76Bullish
- TEMA 10801.42Bearish
- TEMA 20809.84Bearish
- TEMA 50812.33Bearish
- MACD15.44Bearish
- ADX32.94Strong Trend
- IndicatorValueSignal
- RSI58.84Neutral
- CCI45.60Neutral
- ROC 9-2.20Bearish
- ROC 142.96Bullish
- ROC 255.68Bullish
- Stoch K62.69Neutral
- Stoch D63.37Neutral
- IndicatorValueSignal
- BB Upper838.27Neutral
- BB Middle784.60Neutral
- BB Lower730.93Neutral
- ATR9.99Low Volatility
- IndicatorValueSignal
- MFI78.70Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10793.95Bullish
- SMA 20777.61Bullish
- SMA 50730.78Bullish
- EMA 10793.07Bullish
- EMA 20774.87Bullish
- EMA 50750.12Bullish
- DEMA 10809.76Bearish
- DEMA 20805.21Bearish
- DEMA 50766.57Bullish
- TEMA 10807.27Bearish
- TEMA 20816.56Bearish
- TEMA 50785.37Bullish
- MACD22.84Bullish
- ADX37.08Strong Trend
- IndicatorValueSignal
- RSI60.62Neutral
- CCI79.46Neutral
- ROC 96.67Bullish
- ROC 144.05Bullish
- ROC 2516.80Bullish
- Stoch K64.34Neutral
- Stoch D70.03Neutral
- IndicatorValueSignal
- BB Upper828.25Neutral
- BB Middle777.61Neutral
- BB Lower726.97Neutral
- ATR14.94Low Volatility
- IndicatorValueSignal
- MFI66.40Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10781.15Bullish
- SMA 20736.97Bullish
- SMA 50757.15Bullish
- EMA 10776.54Bullish
- EMA 20755.71Bullish
- EMA 50740.43Bullish
- DEMA 10804.95Bearish
- DEMA 20778.43Bullish
- DEMA 50761.95Bullish
- TEMA 10813.61Bearish
- TEMA 20801.35Bearish
- TEMA 50N/AN/A
- MACD20.34Bullish
- ADX29.50Strong Trend
- IndicatorValueSignal
- RSI62.12Neutral
- CCI100.01Overbought
- ROC 94.58Bullish
- ROC 1417.65Bullish
- ROC 2513.48Bullish
- Stoch K84.67Overbought
- Stoch D90.66Overbought
- IndicatorValueSignal
- BB Upper831.77Neutral
- BB Middle736.97Neutral
- BB Lower642.18Neutral
- ATR23.13Low Volatility
- IndicatorValueSignal
- MFI74.95Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10739.66Bullish
- SMA 20731.41Bullish
- SMA 50718.36Bullish
- SMA 100686.14Bullish
- SMA 200719.06Bullish
- EMA 10759.87Bullish
- EMA 20746.22Bullish
- EMA 50724.57Bullish
- EMA 100714.46Bullish
- EMA 200747.81Bullish
- DEMA 10783.98Bullish
- DEMA 20762.22Bullish
- DEMA 50751.59Bullish
- DEMA 100705.68Bullish
- DEMA 200664.35Bullish
- TEMA 10805.43Bearish
- TEMA 20766.55Bullish
- TEMA 50769.84Bullish
- TEMA 100749.85Bullish
- TEMA 200660.36Bullish
- MACD14.05Bullish
- ADX18.76Weak Trend
- IndicatorValueSignal
- RSI59.73Neutral
- CCI149.71Overbought
- ROC 1412.68Bullish
- ROC 2510.94Bullish
- Stoch K87.38Overbought
- Stoch D88.83Overbought
- IndicatorValueSignal
- BB Upper811.19Neutral
- BB Middle731.41Neutral
- BB Lower651.63Neutral
- ATR37.95Low Volatility
- IndicatorValueSignal
- MFI64.60Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 20681.09Bullish
- SMA 50744.90Bearish
- EMA 20704.32Bearish
- EMA 50757.79Bearish
- DEMA 20694.42Bullish
- DEMA 50663.85Bullish
- TEMA 20728.68Bearish
- TEMA 50645.81Bullish
- MACD-3.37Bullish
- ADX20.05Weak Trend
- IndicatorValueSignal
- RSI47.46Neutral
- CCI-40.19Neutral
- ROC 1413.08Bullish
- ROC 25-5.44Bearish
- Stoch K33.21Neutral
- Stoch D44.50Neutral
- IndicatorValueSignal
- BB Upper800.17Neutral
- BB Middle681.09Neutral
- BB Lower562.00Neutral
- ATR86.38Low Volatility
- IndicatorValueSignal
- MFI81.20Overbought
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 6671.08Bullish
- SMA 12746.14Bearish
- SMA 24960.76Bearish
- EMA 6692.66Bullish
- EMA 12755.34Bearish
- EMA 24799.08Bearish
- DEMA 6651.03Bullish
- DEMA 12650.96Bullish
- DEMA 24N/AN/A
- TEMA 6678.88Bullish
- TEMA 12622.66Bullish
- TEMA 24N/AN/A
- MACDN/AN/A
- ADX26.78Strong Trend
- IndicatorValueSignal
- RSI58.32Neutral
- CCIN/AN/A
- ROC 25-24.43Bearish
- ROC 50N/AN/A
- Stoch KN/AN/A
- Stoch DN/AN/A
- IndicatorValueSignal
- BB Upper1389.61Neutral
- BB Middle915.42Neutral
- BB Lower441.24Neutral
- ATR198.06High Volatility
- IndicatorValueSignal
- MFI46.68Neutral